Optinose is scheduled to resume trading at 4:20 pm ET, with quotation set to resume at 4:15 pm, according to Nasdaq. Shares were halted ahead of the company announcing that the U.S. Food and Drug Administration has approved XHANCE nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPTN:
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
- Optinose initiated with a Buy at H.C. Wainwright
- Optinose reports Q4 EPS (9c), consensus (9c)
- Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- Optinose (OPTN) Q4 Earnings Cheat Sheet